Publication date: 22nd April 2022
In the context of the H2020 PRIME project, we developed an immunosensor capable of detecting low levels of analyte in a liquid sample. The prototype can be applied in point of care diagnosis, thanks to its portability, affordability, and ease of use. The device presented a limit of detection between 1 and 5 ng/mL of a model cancer marker (CEA). This immunosensor combines microfluidics, plasmonic nanoparticles, a sandwich immunoassay and heat transduction to generate a visually detectable signal. The capture antibody is conjugated to a functionalized surface included in the design of the prototype. This antibody binds to the analyte when the sample is run through. A NIR-absorbing gold nanoparticle, previously bioconjugated with the detection antibody, is then run through the prototype, forming an immunosandwich if the analyte is present, or being washed away if the analyte is absent. Finally, the prototypes are irradiated with a NIR laser centred to 1064 nm, which induces the nanoparticles to heat. The heat generated in the prototype produces a visible dark signal in a sheet of thermal paper located on the back of the prototype, which is visible to the naked eye without the need to use any reading device.